Many individuals with chronic obstructive pulmonary disease (COPD) are only diagnosed after they experience late-stage exacerbations, but a new tool could hasten the process of diagnosing cases of COPD.
For at least one-third of Americans with chronic obstructive pulmonary disease (COPD) receive late-stage diagnoses after they experience disease exacerbations that eliminate the possibility of an intervention.
However, a professor at the University of Kentucky College of Public Health and a national team of public health experts have developed a tool to hasten the process of diagnosing cases of COPD patients.
“Undiagnosed and untreated COPD can lead to detriments in quality of life, and basically people start doing less because they have difficulty breathing,” David Mannino, MD, FCCP, said in a statement. “Many people attribute this difficulty of breathing to just getting older when, in fact, they may have a disease that is potentially treatable.”
Dr Mannino reported findings of a study examining the 5-step diagnostic tool at the meeting of the European Respiratory Society. A 3-year trial tested the effectiveness of a patient questionnaire posing 5 “yes” or “no” questions related to the patient’s lifestyle, as well as 2 common methods for diagnosing COPD: a peak flow examination and spirometry.
Overall, the study found that the questionnaire paired with peak flow examination was the most effective diagnostic approach. Previous screening methods to diagnose COPD relied on the smoking history of the patient, as well as patient cough and sputum.
Not only could the tool help health providers diagnose COPD in mere seconds, but it could help patients find out if they suffer from COPD symptoms before a visit with the doctor.
Dr Mannino pointed out that in Kentucky not only is there a correlation between high rates of smoking and high rates of COPD, but residents are at a high risk of COPD because of other factors, such as coal mining, environmental dust, and poverty. Next, the researchers will test the effectiveness of the 5-question tool in different populations.
“What we would like to see is that this tool be used certainly in primary care practices,” Dr Mannino said. “There is the potential that this is something that could be used by individuals to screen themselves and sort of give them something to talk about with their physician.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More